BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ICLUSIG (Ponatinib) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ICLUSIG (Ponatinib)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06207123-10794@assetmemo.bio
DTSTAMP:20261121T005848Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:ICLUSIG (Ponatinib): Phase 1/2 readout est. (NCT06207123)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 1/2\, Acute Lymphoblastic Leukemia.
 \nStudy: A Study to Investigate LP-118\, Ponatinib\, Vincristine and Dexam
 ethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymp
 hoblastic Lymphoma (LBL)\nEstimated primary completion: 1 December 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ponatinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06207123
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03739814-10794@assetmemo.bio
DTSTAMP:20261121T005848Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:ICLUSIG (Ponatinib): Phase 2 readout est. (NCT03739814)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 2\, Acute Lymphoblastic Leukemia.\n
 Study: Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in
  Treating Patients With Newly Diagnosed\, Recurrent\, or Refractory CD22-P
 ositive B-Lineage Acute Lymphoblastic Leukemia\nEstimated primary completi
 on: 1 February 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 ponatinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT03739814
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03147612-10794@assetmemo.bio
DTSTAMP:20261121T005848Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:ICLUSIG (Ponatinib): Phase 2 readout est. (NCT03147612)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 2\, Chronic Myeloid Leukemia.\nStud
 y: Low-Intensity Chemotherapy\, Ponatinib and Blinatumomab in Treating Pat
 ients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute 
 Lymphoblastic Leukemia\nEstimated primary completion: 28 February 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/ponatinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT03147612
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04722848-10794@assetmemo.bio
DTSTAMP:20261121T005848Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:ICLUSIG (Ponatinib): Phase 3 readout est. (NCT04722848)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 3\, Acute Lymphoblastic Leukemia.\n
 Study: Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherap
 y and Imatinib in Newly Diagnosed Adult Ph+ ALL\nEstimated primary complet
 ion: September 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 ponatinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04722848
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01424982-10794@assetmemo.bio
DTSTAMP:20261121T005848Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:ICLUSIG (Ponatinib): Phase 2 readout est. (NCT01424982)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 2\, Chronic Myeloid Leukemia.\nStud
 y: Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patien
 ts With Acute Lymphoblastic Leukemia\nEstimated primary completion: 31 Oct
 ober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ponatinib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0142
 4982
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03263572-10794@assetmemo.bio
DTSTAMP:20261121T005848Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:ICLUSIG (Ponatinib): Phase 2 readout est. (NCT03263572)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 2\, Chronic Myeloid Leukemia.\nStud
 y: Blinatumomab\, Methotrexate\, Cytarabine\, and Ponatinib in Treating Pa
 tients With Philadelphia Chromosome-Positive\, or BCR-ABL Positive\, or Re
 lapsed/Refractory\, Acute Lymphoblastic Leukemia\nEstimated primary comple
 tion: 30 November 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/ponatinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT03263572
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03934372-10794@assetmemo.bio
DTSTAMP:20261121T005848Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:ICLUSIG (Ponatinib): Phase 1/2 readout est. (NCT03934372)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 1/2\, Chronic Myeloid Leukemia.\nSt
 udy: Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent
  or Refractory Leukemias\, Lymphomas or Solid Tumors\nEstimated primary co
 mpletion: 1 February 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ponatinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT03934372
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06813079-10794@assetmemo.bio
DTSTAMP:20261121T005848Z
DTSTART;VALUE=DATE:20280217
DTEND;VALUE=DATE:20280218
SUMMARY:ICLUSIG (Ponatinib): Phase 2 readout est. (NCT06813079)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 2.\nStudy: Using Tumor Models to De
 termine Treatments\nEstimated primary completion: 17 February 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/ponatinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06813079
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04747912-10794@assetmemo.bio
DTSTAMP:20261121T005848Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:ICLUSIG (Ponatinib): Phase 2 readout est. (NCT04747912)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 2\, Acute Lymphoblastic Leukemia.\n
 Study: Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphobl
 astic Leukemia With Inotuzumab Ozogamicin (InO)\nEstimated primary complet
 ion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/po
 natinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04747912
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04530565-10794@assetmemo.bio
DTSTAMP:20261121T005848Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:ICLUSIG (Ponatinib): Phase 3 readout est. (NCT04530565)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 3\, Acute Lymphoblastic Leukemia.\n
 Study: Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Bli
 natumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymph
 oblastic Leukemia in Adults\nEstimated primary completion: 1 July 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/ponatinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT04530565
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07224100-10794@assetmemo.bio
DTSTAMP:20261121T005848Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:ICLUSIG (Ponatinib): Phase 2 readout est. (NCT07224100)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 2\, Acute Lymphoblastic Leukemia.\n
 Study: Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for th
 e Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymp
 hoblastic Leukemia/Lymphoma\nEstimated primary completion: 31 July 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ponatinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07224100
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06514534-10794@assetmemo.bio
DTSTAMP:20261121T005848Z
DTSTART;VALUE=DATE:20290217
DTEND;VALUE=DATE:20290218
SUMMARY:ICLUSIG (Ponatinib): Phase 2 readout est. (NCT06514534)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 2\, Chronic Myeloid Leukemia.\nStud
 y: Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I 
 Mutation Who Are Resistant\, Intolerant or Ineligible to Ponatinib.\nEstim
 ated primary completion: 17 February 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/ponatinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06514534
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04070443-10794@assetmemo.bio
DTSTAMP:20261121T005848Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:ICLUSIG (Ponatinib): Phase 2 readout est. (NCT04070443)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 2\, Chronic Myeloid Leukemia.\nStud
 y: Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With 
 Chronic Myelogenous Leukemia in Chronic Phase\nEstimated primary completio
 n: 1 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ponat
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04070443
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06061094-10794@assetmemo.bio
DTSTAMP:20261121T005848Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:ICLUSIG (Ponatinib): Phase 2 readout est. (NCT06061094)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 2\, Acute Lymphoblastic Leukemia.\n
 Study: Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy
 \, Imatinib or Ponatinib\, Blinatumomab and SCT\nEstimated primary complet
 ion: 1 July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pon
 atinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06061094
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01746836-10794@assetmemo.bio
DTSTAMP:20261121T005848Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:ICLUSIG (Ponatinib): Phase 2 readout est. (NCT01746836)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 2\, Chronic Myeloid Leukemia.\nStud
 y: Ponatinib Hydrochloride as Second Line Therapy in Treating Patients Wit
 h Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Ima
 tinib Mesylate\, Dasatinib\, or Nilotinib\nEstimated primary completion: 3
 1 December 2030. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pona
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT01746836
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06860269-10794@assetmemo.bio
DTSTAMP:20261121T005848Z
DTSTART;VALUE=DATE:20350315
DTEND;VALUE=DATE:20350316
SUMMARY:ICLUSIG (Ponatinib): Phase 2/3 readout est. (NCT06860269)
DESCRIPTION:ICLUSIG (Ponatinib)\, phase 2/3\, Acute Lymphoblastic Leukemia.
 \nStudy: A 3-cohort Randomized Study Evaluating the Role of New Immunother
 apeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (
 HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia\nEs
 timated primary completion: 15 March 2035. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/ponatinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06860269
URL:https://assetmemo.bio/drug/ponatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
